Pharmachologic effect (UK experts)
Drug for the treatment of benign prostatic hyperplasia. Dutasteride - dual inhibitor of 5α-reductase. Inhibits the activity of 5α-reductase isoenzymes type 1 and 2, which are responsible for the conversion of testosterone to 5α-dihydrotestosterone (DHT). DHT androgen is the main responsible for hyperplasia prostatic glandular tissue, as experts in the UK say.
The maximum impact of dutasteride to reduce the concentration of DHT is dose dependent and is observed within 1-2 weeks after starting treatment. UK scientists claim: after 1 and 2 weeks of dutasteride dose of 500 mg / day mean values of the serum is reduced by 85% and 90% concentrations of dihydrotestosterone.